Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer.

ABSTRACT: Despite the clinical outcomes being extremely limited, blocking immune inhibitory checkpoint pathways has been in the spotlight as a promising strategy for treating gastrointestinal cancer. However, a distinct strategy for the successful treatment is obviously needed in the clinical settings. Myeloid cells, such as neutrophils, macrophages, dendritic cells, and mast cells, are the majority of cellular components in the human immune system, but have received relatively less attention for the practical implementation than T cells and NK cells in cancer therapy because of concentration of the interest in development of the immune checkpoint blocking antibody inhibitors (ICIs). Abnormality of myeloid cells must impact on the entire host, including immune responses, stromagenesis, and cancer ce

SUBMITTER: Kudo-Saito C 

PROVIDER: S-EPMC9539086 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature